LENZ Therapeutics, Inc. (LENZ) Investor Relations Documents

LENZ Therapeutics, Inc. (LENZ) investor relations documents from the company's IR site: 1 presentation, 37 press releases. Read in-app with summaries. First-party data.

Key Opinion Leader Presentation of Capstone Data from Phase 3 CLARITY Study: LENZ Therapeutics KOL presentation detailing Phase 3 CLARITY study results for LNZ001 and LNZ002, demonstrating efficacy in treating presbyopia.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releaseLENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-04Press releaseLENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
2026-07-06Press releaseLENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Tr
2026-06-24Press releaseLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Au
2026-06-07Press releaseLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater Chi
2026-05-26Press releaseLENZ Therapeutics to Participate in Upcoming Investor Conferences
2026-05-26Press releaseDownload as PDF
2026-05-11Press releaseLENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-11Press releasePDF
2026-05-04Press releaseLENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Att
2026-04-20Press releaseLENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products R
2026-03-24Press releaseLENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
2026-03-24Press releasePDF
2026-03-24Press releasePDF
2026-03-17Press releaseLENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March
2026-03-10Press releaseLENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for
2026-01-14Press releaseLENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign
2026-01-07Press releaseLENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
2025-11-05Press releasePDF
2025-07-30Press releasePDF
2025-05-07Press releasePDF
2025-05-06Press releaseLENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
2025-03-19Press releaseLENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
2025-03-19Press releasePDF
2025-03-11Press releaseLENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March
2025-03-03Press releaseLENZ Therapeutics to Host Commercial Day on April 15, 2025
2024-11-06Press releasePDF
2024-10-30Press releaseLENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
2024-08-14Press releasePDF
2024-08-14Press releaseLENZ Therapeutics Reports Second Quarter 2024 Financial Results
2024-08-07Press releaseLENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
2024-06-10Press releaseLENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
2024-05-30Press releaseLENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
2024-05-08Press releasePDF
2024-05-08Press releaseLENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
2024-05-01Press releaseLENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
PresentationKey Opinion Leader Presentation of Capstone Data from Phase 3 CLARITY Study
Press releaseLENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

LENZ overview · LENZ earnings · LENZ financials · LENZ KPIs · LENZ ownership · LENZ peers · LENZ filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.